Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sankyo Aims at US Sales of \360 Bil. in FY2010
November 19, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 19, 2001
- Shionogi to Increase Overseas Sales to 10% of Total Sales in 2005
November 19, 2001
- NEW PRODUCTS
November 19, 2001
- Otsuka, BMS File NDA for New Antipsychotic Aripiprazole with FDA
November 19, 2001
- Philips Medical Launches New Stethoscopes
November 19, 2001
- Japanese Global Strategy Update (7)
November 19, 2001
- Regulations Related to Medical Devices to Be Reviewed
November 19, 2001
- Takeda: 7.7% Sales Increase Attributable to Int'l Strategic Products
November 19, 2001
- Terumo: Sales Up 7.3%, Profits Down
November 19, 2001
- Santen: Independent Marketing in US Pushes Up Sales
November 19, 2001
- Iressa Effective against NSCLC: PII Results in Int'l Joint Trial
November 19, 2001
- Makers Rush to Apply for Anthrax as Additional Indication
November 19, 2001
- Takeda to Set Up Facility for Gene, Protein Function Analysis
November 19, 2001
- Mitsubishi Research Institute Launches Coding Software Based on Ethical GL
November 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 19, 2001
- BUSINESS NEWS IN BRIEF
November 19, 2001
- Greencross-coa: Sales Up 21% to \23.4 Bil.
November 19, 2001
- OBITUARY
November 19, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 19, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…